Anpheros Search · Treatment

Loxapine

Also known as: Adasuve

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder, and patients should receive regular treatment immediately after control of acute agitation symptoms. In the United States, loxapine capsules are indicated for the treatment of schizophrenia, with efficacy established in clinical studies of newly hospitalized and chronically hospitalized acutely ill patients. Loxapine is also listed by the cited source as having an approved use for schizophrenia.

From: Source: European Medicines Agency (EMA), Adasuve — EPAR, 09/10/2025. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm
6475 loxapine
EMA
EMEA/H/C/002400

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Adasuve

Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.

Source: European Medicines Agency (EMA), Adasuve — EPAR, 09/10/2025. © European Medicines Agency.

Document date: 09/10/2025 · Official document →

FDA (USA) Loxapine

INDICATIONS AND USAGE Loxapine capsules are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.

Data provided by the U.S. Food and Drug Administration.

Document date: 20260903 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Loxapine approved for in the European Union?

Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. (Source: European Medicines Agency (EMA), Adasuve — EPAR, 09/10/2025. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • Data provided by the U.S. Food and Drug Administration.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Adasuve — EPAR, 09/10/2025. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →